Actuate Therapeutics (NASDAQ:ACTU) Shares Up 0.5% - What's Next?

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) shares rose 0.5% during trading on Thursday . The stock traded as high as $7.33 and last traded at $6.26. Approximately 618,575 shares traded hands during trading, an increase of 917% from the average daily volume of 60,817 shares. The stock had previously closed at $6.23.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ACTU. HC Wainwright increased their target price on Actuate Therapeutics to $20.00 and gave the company a "buy" rating in a research note on Tuesday, June 3rd. Craig Hallum started coverage on Actuate Therapeutics in a research note on Tuesday, April 22nd. They issued a "buy" rating and a $21.00 price target for the company.

Actuate Therapeutics Stock Performance

The stock has a 50-day moving average price of $8.21 and a 200-day moving average price of $8.16.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.06).

Insider Buying and Selling

In other news, Director Aaron G.L. Fletcher purchased 71,428 shares of Actuate Therapeutics stock in a transaction that occurred on Friday, June 27th. The shares were bought at an average cost of $7.00 per share, with a total value of $499,996.00. Following the completion of the purchase, the director directly owned 196,428 shares in the company, valued at approximately $1,374,996. This trade represents a 57.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Equity Cof Lp Bios purchased 71,428 shares of the firm's stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average cost of $7.00 per share, with a total value of $499,996.00. Following the completion of the purchase, the director directly owned 196,428 shares in the company, valued at $1,374,996. The trade was a 57.14% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 214,284 shares of company stock worth $1,499,988 in the last ninety days. Corporate insiders own 69.34% of the company's stock.

Institutional Investors Weigh In On Actuate Therapeutics

Several large investors have recently bought and sold shares of the company. Gleason Group Inc. bought a new stake in shares of Actuate Therapeutics during the second quarter valued at about $116,000. Goldman Sachs Group Inc. increased its stake in shares of Actuate Therapeutics by 98.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock worth $151,000 after acquiring an additional 11,105 shares during the last quarter. Voss Capital LP boosted its stake in shares of Actuate Therapeutics by 157.7% in the 1st quarter. Voss Capital LP now owns 142,381 shares of the company's stock valued at $964,000 after buying an additional 87,135 shares during the period. Chicago Partners Investment Group LLC purchased a new stake in shares of Actuate Therapeutics in the first quarter valued at approximately $70,000. Finally, Sfmg LLC purchased a new stake in shares of Actuate Therapeutics in the first quarter worth about $74,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.